We are pleased and very grateful that more than 2,000 great people enrich the GBA Group with their ideas, perspectives, life stories and knowledge. Each of them brings his or her own personality and is therefore an important individual piece of the puzzle for our joint success. By treating each other with openness, tolerance and respect, we move forward and develop GBA Group as a unique international company.

International Tea Day is celebrated on May 21 and on the occasion of this day we would like to offer you an insight into our analysis portfolio for tea analytics at GBA Group.

As tea is one of the most consumed luxury foods worldwide, the verification of safety and quality is of great importance. In the tea industry, analytical requirements are constantly changing because almost any plant product, whether herbs, spices, fruits or vegetables, can be used in tea blends.

Effective March 1st, 2023, Dr. Timo Lebold and Felix Bunde have been appointed to the management of GBA Medical Device Services GmbH. By this, long-term experience in the medical device industry is combined with experience in business administration, strategic development, controlling, and project management.

Dr. Lebold and Mr. Bunde will further support the growth of GBA Medical Device Services GmbH to enable continuing of providing the high-quality service that defines MDS.

In terms of the daily business operations, nothing has changed for you. Test reports as well as other official documents will be updated successively. There is no need to adapt the contracts.

Covid19 changed many of the established procedures. Study designs also had to be adapted to the new reality of conducting clinical trials. This was accompanied by an increase in the integration and use of digital structures in clinical trials. Patients could no longer visit the trial centre, so telephone and video visits were introduced. Monitors could not visit the trial sites, so new ways had to be found to ensure data quality.

Some of these innovations have proven to be helpful and beneficial to trials, for example by facilitating patient recruitment, increasing patient retention and saving time and money. These are benefits that are hard to resist, and the trend is moving away from traditional trials and towards decentralised or hybrid trials.

However, with new concepts come new questions and obstacles that need to be considered and solved. LKF, ABF and AMEDON, have worked together in a workshop to develop solutions that we adapt to our customers' needs.

Memnoniella echinata is a mold with worldwide distribution that has often been isolated from clothing or carpets indoors. The species is not among the officially recognized indoor moisture indicators. An increased detection of Memnoniella echinata can therefore be an indication of increased moisture in the interior. Concrete data on the aW value are not known. According to TRBA 460, the mold species Memnoniella echinata is classified in biological risk group 1. Thus, there is no known increased risk of infection for humans.